title: Effectivity of long antigen exposition dendritic cell therapy (LANEXDC®) in the palliative treatment of pancreatic cancer.
abstract: OBJECTIVE
  In pancreatic cancer median survival times range around 6, 6 to 6,9 months. Here we retrospectively analyzed the outcome of immunotherapy in the additional palliative treatment of pancreatic cancer with long antigen exposition dendritic cell therapy (LANEX-DC(®)) in 138 patients who were treated at our institution.
  
  
  METHODS
  Data were available of 134 patients (97.1%). The median interval between first diagnosis and start of treatment was 1.4 months.
  
  
  RESULTS
  Therapy was well tolerated and no serious side effects were observed. The survival rate after 6 months was 72.2 % and afters 9 month 50.4%. The median survival time according to Kaplan- Meier regression analysis was 8.9 months. Median survival was significantly higher in the group of patients who started immunotherapy within 2 months following diagnosis (p=0.029) or repeated immunotherapy (p=0.027). Interestingly, younger patients <= 60 years of age lived significantly longer as patients > 60 years of age (p = 0.022).
  
  
  CONCLUSIONS
  We were able to demonstrate in a large retrospective analysis that additional treatment with dendritic cells (LANEX-DC(®)) is highly effective and extends the median survival times up to 8.9 months. Furthermore we were able to demonstrate that median survival can be increased by early beginning and repetition of LANEX-DC(®) treatment.
authors.affiliation: Center for oncologic, endocrine and minimal-invasive surgery, Silcherstr. 36, 89231 Neu-Ulm, Germany. frank.gansauge@eurosurgery.de.
authors.forename: F
authors.initials: F
authors.lastname: Gansauge
authors.forename: B
authors.initials: B
authors.lastname: Poch
authors.forename: R
authors.initials: R
authors.lastname: Kleef
authors.forename: M
authors.initials: M
authors.lastname: Schwarz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D016207:Cytokines / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D003713:Dendritic Cells / Q000166:cytology* / Q000187:drug effects / Q000637:transplantation; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology; D012189:Retrospective Studies; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D016207:Cytokines; D011994:Recombinant Proteins; D003841:Deoxycytidine; D000093542:Gemcitabine